Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Osteo Arthritis Knee
- Main trialPhase 1/2
- “The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.”In the company’s words, NCT04750252 on ClinicalTrials.gov
Other drugs for Osteo Arthritis Knee
- JOINTSTEMR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up1
- 31 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 31 Aug 2027 | Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026